Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
ZTS
$166.66
Zoetis Inc Cl A
$2.25
1.37%
ZTS
Earnings Whisper ®
N/A
4th Quarter December 2024
Consensus: $1.38
Revenue: $2.32 Bil
Thursday
Feb 13
7:00 AM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Monday, November 4, 2024
Zoetis Announces Third Quarter 2024 Results
What do you expect when ZTS reports earnings?
Beat
Meet
Miss
Where is ZTS's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
$172.73
$169.94
$167.17
$164.38
Support
$161.61
$158.82
$156.05
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
Zoetis Inc. is a leader in the animal health space with a focus on both livestock and companion animals in seven major product categories: vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. Zoetis has a diversified business, which caters to eight core species ' cattle, swine, poultry, fish and sheep (collectively, livestock) and dogs, cats and horses (collectively, companion animals). It directly markets its products to veterinarians and livestock producers. The outstanding growth rate in the companion animal medicines, vaccines and diagnostics sector is being driven by economic development, related increases in disposable income and a rise in pet ownership and spending on pet care.Zoetis has been working on strengthening its product portfolio through acquisitions and deals.
Peers
Vertex Pharmaceuticals
BioMarin Pharmaceutical
ARRAY Technologies
Regeneron Pharmaceuticals
Merck & Co.
Bristol Myers Squibb
Eli Lilly
Pfizer
Johnson & Johnson
Ultragenyx Pharmaceutical
Expectations
›
Zoetis Inc Cl A